These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 18240539)
21. Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL. Kassem A; Lindholm C; Lerner UH PLoS One; 2016; 11(6):e0156708. PubMed ID: 27311019 [TBL] [Abstract][Full Text] [Related]
22. Phloretin promotes osteoclast apoptosis in murine macrophages and inhibits estrogen deficiency-induced osteoporosis in mice. Lee EJ; Kim JL; Kim YH; Kang MK; Gong JH; Kang YH Phytomedicine; 2014 Sep; 21(10):1208-15. PubMed ID: 24932975 [TBL] [Abstract][Full Text] [Related]
23. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. Yu X; Huang Y; Collin-Osdoby P; Osdoby P J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451 [TBL] [Abstract][Full Text] [Related]
24. Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage. Raimondo A; Lembo S; Di Caprio R; Donnarumma G; Monfrecola G; Balato N; Ayala F; Balato A Eur J Immunol; 2017 Jun; 47(6):1062-1074. PubMed ID: 28386999 [TBL] [Abstract][Full Text] [Related]
25. Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. Viereck V; Gründker C; Friess SC; Frosch KH; Raddatz D; Schoppet M; Nisslein T; Emons G; Hofbauer LC J Bone Miner Res; 2005 Nov; 20(11):2036-43. PubMed ID: 16234977 [TBL] [Abstract][Full Text] [Related]
26. Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL/RANK interactions and reduces ovariectomy-induced bone loss in mice. Liu C; Chen X; Zhi X; Weng W; Li Q; Li X; Zou Y; Su J; Hu HG Eur J Med Chem; 2018 Feb; 145():661-672. PubMed ID: 29348072 [TBL] [Abstract][Full Text] [Related]
28. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Taxel P; Kaneko H; Lee SK; Aguila HL; Raisz LG; Lorenzo JA Osteoporos Int; 2008 Feb; 19(2):193-9. PubMed ID: 17768586 [TBL] [Abstract][Full Text] [Related]
29. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Osako MK; Nakagami H; Koibuchi N; Shimizu H; Nakagami F; Koriyama H; Shimamura M; Miyake T; Rakugi H; Morishita R Circ Res; 2010 Aug; 107(4):466-75. PubMed ID: 20595654 [TBL] [Abstract][Full Text] [Related]
30. [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. Kapczuk K; Sowińska-Przepiera E; Friebe Z Ginekol Pol; 2003 Apr; 74(4):323-31. PubMed ID: 12916277 [TBL] [Abstract][Full Text] [Related]
31. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. Roux S; Mariette X Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989 [TBL] [Abstract][Full Text] [Related]
32. Postmenopausal osteoporosis in rheumatoid arthritis: The estrogen deficiency-immune mechanisms link. Sapir-Koren R; Livshits G Bone; 2017 Oct; 103():102-115. PubMed ID: 28666971 [TBL] [Abstract][Full Text] [Related]
33. Are Oxidative Stress and Inflammation Mediators of Bone Loss Due to Estrogen Deficiency? A Review of Current Evidence. Mohamad NV; Ima-Nirwana S; Chin KY Endocr Metab Immune Disord Drug Targets; 2020; 20(9):1478-1487. PubMed ID: 32496996 [TBL] [Abstract][Full Text] [Related]
34. [The impact of controlling bone remodeling in rheumatoid arthritis.]. Ebina K Clin Calcium; 2017; 27(12):1739-1744. PubMed ID: 29179168 [TBL] [Abstract][Full Text] [Related]
35. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis. Hsieh TP; Sheu SY; Sun JS; Chen MH Phytomedicine; 2011 Jan; 18(2-3):176-85. PubMed ID: 20554188 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of anti-IL-23 monotherapy versus combination therapy with anti-IL-17 in estrogen deficiency induced bone loss conditions. Shukla P; Mansoori MN; Singh D Bone; 2018 May; 110():84-95. PubMed ID: 29414600 [TBL] [Abstract][Full Text] [Related]
37. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo. Baek JM; Kim JY; Yoon KH; Oh J; Lee MS Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631 [TBL] [Abstract][Full Text] [Related]
38. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542 [TBL] [Abstract][Full Text] [Related]
39. Mechanism Underlying Post-menopausal Osteoporosis: HIF1α is Required for Osteoclast Activation by Estrogen Deficiency. Miyamoto T Keio J Med; 2015; 64(3):44-7. PubMed ID: 26255954 [TBL] [Abstract][Full Text] [Related]
40. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis. Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]